The U.S. Food and Drug Administration (FDA) has approved the use of Letrozene FERTILIZER, a potent fertility medication, for treating advanced prostate cancer.
The FDA approved the drug in May 2018 and it was approved by the U.K. and Canada in July 2018.
The drug works by increasing the level of the hormone estrogen in the blood.
approved Letrozy for treatment of the condition in December 2017, and it is approved by Japan in May 2019.
In the U., the treatment has shown success in reducing the risk of dying from prostate cancer, but there have been a few reports of side effects.
The new drug could be approved in the U,D.C., area in 2020.
FDA approved Letrazolane FERTilizer in May, 2018, for treatment and prevention of prostate cancer and metastatic disease.
The drugs makers say that it is the first product approved by FDA to treat advanced prostate carcinoma.
It works by reducing the levels of estrogen in blood, lowering the amount of estrogen produced, and reducing the amount that is released to the bloodstream.
“Patients treated with Letroze FERTIMEN have reported a marked reduction in their risk of death from prostate carcinomas,” the FDA said in a statement on its website.
The drug is currently available in the United Kingdom and Canada, and a trial is planned in Australia.
The agency did not say when the first patients could get the drug.
According to the FDA, Letrozed is “a potent, long-acting and well tolerated fertility treatment” that has been shown to reduce the risk for dying from cancers of the prostate and other organs.
It is approved for use in women aged 45 to 50, men aged 60 to 70, and for people who have had at least one previous treatment for prostate cancer (men aged 45 and over, women aged 60 and over).
It can also be used for treatment for conditions such as endometriosis, which affects the lining of the uterus, according to the agency.
In a statement, the drug’s manufacturer said that it was working with the FDA to get the approval.
It is not clear how much Letrozi would cost, but according to a study from the American Cancer Society, it costs $4,800 to treat a person in the US for a single treatment.
There is currently no treatment that can treat advanced stage prostate cancer without killing the cancer cells, but if Letroza is approved, it will be the first treatment approved for treatment, said Dr. Jennifer A. Crouch, a cancer expert and director of the Mayo Clinic Cancer Center in Rochester, Minnesota.
Letroze has a number of potential side effects, including an increased risk of stomach bleeding and nausea, according a review of the drug published by the journal, Cancer Research.
For women, the most common side effects are fatigue, bloating, headaches, neck stiffness and weight gain.
There is also concern about an increased chance of bleeding, or a recurrence of bleeding in the first year after treatment, the Mayo Clinics report said.
As a side effect, patients taking Letrozo also have a lower chance of developing kidney stones and kidney problems, and may have more skin rash, the review said.
“The results of our study showed that most patients respond to treatment with minimal side effects,” Dr. John F. Miller, an oncologist at Memorial Sloan Kettering Cancer Center, told CBS News in a phone interview.
“And that includes those who are taking it for multiple treatments.”
The new treatment could help to reduce prostate cancer mortality, according the FDA.
Currently, there are no FDA-approved treatments for prostate cancers, although there are a few approved for other conditions such, Hodgkin’s lymphoma, multiple myeloma, and pancreatic cancer.